- Home
- ZYXI vs RIGL Comparison
ZYXI vs RIGL Comparison
Compare ZYXI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYXI
- RIGL
- Stock Information
- Founded
- ZYXI 1996
- RIGL 1996
- Country
- ZYXI United States
- RIGL United States
- Employees
- ZYXI N/A
- RIGL N/A
- Industry
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ZYXI Health Care
- RIGL Health Care
- Exchange
- ZYXI Nasdaq
- RIGL Nasdaq
- Market Cap
- ZYXI 257.1M
- RIGL 247.1M
- IPO Year
- ZYXI N/A
- RIGL 2000
- Fundamental
- Price
- ZYXI $8.95
- RIGL $21.83
- Analyst Decision
- ZYXI Strong Buy
- RIGL Buy
- Analyst Count
- ZYXI 2
- RIGL 4
- Target Price
- ZYXI $14.00
- RIGL $31.13
- AVG Volume (30 Days)
- ZYXI 120.1K
- RIGL 103.3K
- Earning Date
- ZYXI 10-24-2024
- RIGL 11-07-2024
- Dividend Yield
- ZYXI N/A
- RIGL N/A
- EPS Growth
- ZYXI N/A
- RIGL N/A
- EPS
- ZYXI 0.15
- RIGL N/A
- Revenue
- ZYXI $193,665,000.00
- RIGL $130,201,000.00
- Revenue This Year
- ZYXI $10.70
- RIGL $38.26
- Revenue Next Year
- ZYXI $19.78
- RIGL $24.21
- P/E Ratio
- ZYXI $60.06
- RIGL N/A
- Revenue Growth
- ZYXI 4.21
- RIGL 7.48
- 52 Week Low
- ZYXI $7.15
- RIGL $7.48
- 52 Week High
- ZYXI $13.77
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- ZYXI 54.55
- RIGL 54.17
- Support Level
- ZYXI $7.97
- RIGL $13.91
- Resistance Level
- ZYXI $9.30
- RIGL $15.37
- Average True Range (ATR)
- ZYXI 0.39
- RIGL 0.53
- MACD
- ZYXI 0.01
- RIGL 0.00
- Stochastic Oscillator
- ZYXI 55.17
- RIGL 78.13
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.